These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12081616)

  • 1. Challenges associated with the evaluation of veterinary product bioequivalence: an AAVPT perspective.
    Martinez M; Langston C; Martin T; Conner D
    J Vet Pharmacol Ther; 2002 Jun; 25(3):201-20. PubMed ID: 12081616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2010 AAVPT/EAVPT/ECVPT bioequivalence workshop.
    Martinez M; Hunter RP; Baynes R; Bermingham E; Claxton R; Cole C; Del Castillo J; Gehring R; Harshman K; Lainesse C; Lucas A; Modric S; Robinson J
    J Vet Pharmacol Ther; 2011 Apr; 34(2):105-7. PubMed ID: 21395599
    [No Abstract]   [Full Text] [Related]  

  • 3. Current challenges facing the determination of product bioequivalence in veterinary medicine.
    Martinez MN; Hunter RP
    J Vet Pharmacol Ther; 2010 Oct; 33(5):418-33. PubMed ID: 20840385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating product bioequivalence for highly variable veterinary drugs.
    Claxton R; Cook J; Endrenyi L; Lucas A; Martinez MN; Sutton SC
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():11-6. PubMed ID: 22413787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence accomplishments, ongoing initiatives, and remaining challenges.
    Martinez MN
    J Vet Pharmacol Ther; 2014 Feb; 37(1):2-12. PubMed ID: 23841644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demonstrating comparative in vitro bioequivalence for animal drug products through chemistry and manufacturing controls and physicochemical characterization: a proposal.
    Martinez MN; Fahmy R
    AAPS J; 2015 Mar; 17(2):307-12. PubMed ID: 25609223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges obtaining a biowaiver for topical veterinary dosage forms.
    Baynes R; Riviere J; Franz T; Monteiro-Riviere N; Lehman P; Peyrou M; Toutain PL
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():103-14. PubMed ID: 22413798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International veterinary bioequivalence guideline similarities and differences between Australia, Canada, Europe, Japan, New Zealand and the United States.
    Lainesse C
    AAPS J; 2012 Dec; 14(4):792-8. PubMed ID: 22864669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veterinary drug bioequivalence determination.
    Toutain PL; Koritz GD
    J Vet Pharmacol Ther; 1997 Apr; 20(2):79-90. PubMed ID: 9131533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and bioequivalence: an FDA regulatory overview.
    Chen ML; Shah V; Patnaik R; Adams W; Hussain A; Conner D; Mehta M; Malinowski H; Lazor J; Huang SM; Hare D; Lesko L; Sporn D; Williams R
    Pharm Res; 2001 Dec; 18(12):1645-50. PubMed ID: 11785681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence and generic prescribing: an industrial view.
    Pidgen A
    J Pharm Pharmacol; 1996 Jan; 48(1):11-6. PubMed ID: 8722487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A generic drug primer: regulatory aspects and scientific concepts.
    Henderson JD; White GL
    Mil Med; 1998 Apr; 163(4):193-7. PubMed ID: 9575760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of developmental approaches to companion animal antimicrobials: providing for the unmet therapeutic needs of dogs and cats.
    ; Apley M; Claxton R; Davis C; DeVeau I; Donecker J; Lucas A; Neal A; Papich M
    J Vet Pharmacol Ther; 2010 Apr; 33(2):196-201. PubMed ID: 20444045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the European Medicines Agency's Development of Product-Specific Bioequivalence Guidelines.
    Sullivan JO; Blake K; Berntgen M; Salmonson T; Welink J;
    Clin Pharmacol Ther; 2018 Sep; 104(3):539-545. PubMed ID: 29319156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of bioequivalence study regulatory requirements for human and veterinary drugs.
    Grabowski T; Marczak M; Jaroszewski JJ; Whitmire M
    Regul Toxicol Pharmacol; 2012 Nov; 64(2):233-42. PubMed ID: 22917973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.
    Marzo A; Balant LP
    Arzneimittelforschung; 1995 Feb; 45(2):109-15. PubMed ID: 7710428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A SAS/IML program for simulating pharmacokinetic data.
    Russek-Cohen E; Martinez MN; Nevius AB
    Comput Methods Programs Biomed; 2005 Apr; 78(1):39-60. PubMed ID: 15780889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.
    Tothfalusi L; Endrenyi L; Arieta AG
    Clin Pharmacokinet; 2009; 48(11):725-43. PubMed ID: 19817502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the scientific issues embedded in the generic drug approval process.
    Welage LS; Kirking DM; Ascione FJ; Gaither CA
    J Am Pharm Assoc (Wash); 2001; 41(6):856-67. PubMed ID: 11765111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence and other unresolved issues in generic drug substitution.
    Meredith P
    Clin Ther; 2003 Nov; 25(11):2875-90. PubMed ID: 14693311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.